Guinevere Q. Lee, PhD

Highlights

1
Nature communications · 2024
GQGuinevere Q. Lee ZCZhengming Chen BJBrad Jones
PMID: 38956017PMCID: PMC11219899DOIFirst author15 citations
2
Methods in molecular biology (Clifton, N.J.) · 2022
GQGuinevere Q. Lee
PMID: 34985675PMCID: PMC9135474DOIFirst author13 citations
3
AIDS (London, England) · 2021
GQGuinevere Q. Lee
PMID: 33635845PMCID: PMC8102316DOISenior author16 citations

58

8 grants

Co-I
Subtype C HIV-1 Reservoir in Pregnancy-specific Compartments
National Institute of Allergy and Infectious Diseases · 2026–2031
R01AI203452-01
KP
Columbia University-Weill Cornell Medicine CFAR (CU-WCM CFAR)
National Institute of Allergy and Infectious Diseases · 2026–2031 · via Columbia University
P30AI191337-01A1
Sub-PI
Defective HIV-1 proviral abundance and their immune effects in children and adolescents living with perinatal HIV-1
National Institute of Allergy and Infectious Diseases · 2026–2031 · via The Johns Hopkins University
R01AI198053-01
PI
Viral Genetic Determinants of HIV Transcription Control in the Context of HIV Cure
National Institute of Allergy and Infectious Diseases · 2026–2030
R01AI203543-01
Sub-PI
Impact of Neonatal ART and Broadly Neutralizing Antibodies on HIV-1 Reservoirs in Infants: Towards ART-free Remission
National Institute of Allergy and Infectious Diseases · 2024–2029 · via The Johns Hopkins University
R01AI186792-03
PI
Patterns of HIV archival drug resistance in intact versus defective proviral DNA genomes
Merck & Co., Inc. · 2025–2028Contract
SRA 242601-01
Co-I
REACH: Research Enterprise to Advance a Cure for HIV
National Institute of Allergy and Infectious Diseases · 2021–2027· 2 renewals
UM1AI164565-06
PI
Characterization of Non-subtype B HIV-1 Reservoirs and its Association with Longitudinal Clinical Outcomes
National Institute of Allergy and Infectious Diseases · 2021–2027
R01AI162221-05

Completed grants (7)

Sub-PI
Genetic and functional differences between the long terminal repeat transcriptional promoters of intact HIV-1 subtypes B, C and AG proviruses
Bill & Melinda Gates Foundation · 2023–2024 · via Africa Health Research Institute
AHRI 243012-01
Sub-PI
Characterizing non-direct antiviral functions of bNAbs
amfAR · 2023–2024 · via The Regents of the University of California, San Francisco
110560-74-RPRL
PI
Insights into the dynamics of clonal expansion of genome-intact proviruses by examining longitudinal evolution of HIV proviral DNA compositions
National Institute of Allergy and Infectious Diseases · 2020–2023
R21AI150398-02
KP
BELIEVE: Bench to Bed Enhanced Lymphocyte Infusions to Engineer Viral Eradication
National Institute of Allergy and Infectious Diseases · 2018–2023
UM1AI126617-03
PI
The LOVE Study: hyperacute and longitudinal dynamics of SARS-CoV-2 viral load and host immune responses in high-risk health care workers
Merck & Co., Inc. · 2021–2023Contract
SRA 204570-01
PI
Identification of innate-like T cell as a novel HIV reservoir
CRDF Global · 2021–2023
DAA3-20-66948-1
Co-I
Defining & Characterizing Novel Mechanisms by which HIV-infected Primary CD4+ T-cells Intrinsically Resist Elimination by CTL
National Institute of Allergy and Infectious Diseases · 2020–2022
No publications yet
R01AI152764-01A1

2

Completed & closed trials (2)

PI
The LOVE Study: hyperacute and longitudinal dynamics of SARS-CoV-2 viral load and host immune responses in high-risk health care workers
Weill Medical College of Cornell University · IRB STUDY CLOSURE (as of 2021)
PI
Association of HIV-1 viral genome sequence diversity with host genotypes and clinical outcomes
National Institute of Mental Health · CLOSED TO ACCRUAL (as of 2020)

New Therapy May Effectively Control HIV in Uganda
February 19, 2025
A multi-national, multi-institutional study led by Weill Cornell Medicine investigators found little natural resistance to a new HIV therapy called lenacapavir in a population of patients in Uganda.
New Lab Test to Detect Persistent HIV Strains in Africa May Aid Search for Cure
July 2, 2024
A multinational team led by Weill Cornell Medicine investigators developed a test that will help measure the persistence of HIV in people affected by viral strains found predominantly in Africa—a vital tool in the search for an HIV cure that will benefit patients around the world.

1